225 related articles for article (PubMed ID: 18593912)
1. Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance.
Shachaf CM; Gentles AJ; Elchuri S; Sahoo D; Soen Y; Sharpe O; Perez OD; Chang M; Mitchel D; Robinson WH; Dill D; Nolan GP; Plevritis SK; Felsher DW
Cancer Res; 2008 Jul; 68(13):5132-42. PubMed ID: 18593912
[TBL] [Abstract][Full Text] [Related]
2. Combined analysis of murine and human microarrays and ChIP analysis reveals genes associated with the ability of MYC to maintain tumorigenesis.
Wu CH; Sahoo D; Arvanitis C; Bradon N; Dill DL; Felsher DW
PLoS Genet; 2008 Jun; 4(6):e1000090. PubMed ID: 18535662
[TBL] [Abstract][Full Text] [Related]
3. Decoding c-Myc networks of cell cycle and apoptosis regulated genes in a transgenic mouse model of papillary lung adenocarcinomas.
Ciribilli Y; Singh P; Spanel R; Inga A; Borlak J
Oncotarget; 2015 Oct; 6(31):31569-92. PubMed ID: 26427040
[TBL] [Abstract][Full Text] [Related]
4. GLIPR1 suppresses prostate cancer development through targeted oncoprotein destruction.
Li L; Ren C; Yang G; Fattah EA; Goltsov AA; Kim SM; Lee JS; Park S; Demayo FJ; Ittmann MM; Troncoso P; Thompson TC
Cancer Res; 2011 Dec; 71(24):7694-704. PubMed ID: 22025562
[TBL] [Abstract][Full Text] [Related]
5. Gene expression profiling of MYC-driven tumor signatures in porcine liver stem cells by transcriptome sequencing.
Aravalli RN; Talbot NC; Steer CJ
World J Gastroenterol; 2015 Feb; 21(7):2011-29. PubMed ID: 25717234
[TBL] [Abstract][Full Text] [Related]
6. Reversible kinetic analysis of Myc targets in vivo provides novel insights into Myc-mediated tumorigenesis.
Lawlor ER; Soucek L; Brown-Swigart L; Shchors K; Bialucha CU; Evan GI
Cancer Res; 2006 May; 66(9):4591-601. PubMed ID: 16651409
[TBL] [Abstract][Full Text] [Related]
7. Developmental context determines latency of MYC-induced tumorigenesis.
Beer S; Zetterberg A; Ihrie RA; McTaggart RA; Yang Q; Bradon N; Arvanitis C; Attardi LD; Feng S; Ruebner B; Cardiff RD; Felsher DW
PLoS Biol; 2004 Nov; 2(11):e332. PubMed ID: 15455033
[TBL] [Abstract][Full Text] [Related]
8. CDDO-Imidazolide inhibits growth and survival of c-Myc-induced mouse B cell and plasma cell neoplasms.
Han SS; Peng L; Chung ST; DuBois W; Maeng SH; Shaffer AL; Sporn MB; Janz S
Mol Cancer; 2006 Jun; 5():22. PubMed ID: 16759389
[TBL] [Abstract][Full Text] [Related]
9. LncRNA THOR acts as a retinoblastoma promoter through enhancing the combination of c-myc mRNA and IGF2BP1 protein.
Shang Y
Biomed Pharmacother; 2018 Oct; 106():1243-1249. PubMed ID: 30119193
[TBL] [Abstract][Full Text] [Related]
10. Targeting miR-21 with NL101 blocks c-Myc/Mxd1 loop and inhibits the growth of B cell lymphoma.
Li S; He X; Gan Y; Zhang J; Gao F; Lin L; Qiu X; Yu T; Zhang X; Chen P; Tong J; Qian W; Xu Y
Theranostics; 2021; 11(7):3439-3451. PubMed ID: 33537096
[No Abstract] [Full Text] [Related]
11. Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification.
Kim YH; Girard L; Giacomini CP; Wang P; Hernandez-Boussard T; Tibshirani R; Minna JD; Pollack JR
Oncogene; 2006 Jan; 25(1):130-8. PubMed ID: 16116477
[TBL] [Abstract][Full Text] [Related]
12. miR-296-3p Negatively Regulated by Nicotine Stimulates Cytoplasmic Translocation of c-Myc via MK2 to Suppress Chemotherapy Resistance.
Deng X; Liu Z; Liu X; Fu Q; Deng T; Lu J; Liu Y; Liang Z; Jiang Q; Cheng C; Fang W
Mol Ther; 2018 Apr; 26(4):1066-1081. PubMed ID: 29525743
[TBL] [Abstract][Full Text] [Related]
13. Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc.
Sharma VM; Calvo JA; Draheim KM; Cunningham LA; Hermance N; Beverly L; Krishnamoorthy V; Bhasin M; Capobianco AJ; Kelliher MA
Mol Cell Biol; 2006 Nov; 26(21):8022-31. PubMed ID: 16954387
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors.
Marampon F; Ciccarelli C; Zani BM
Mol Cancer; 2006 Aug; 5():31. PubMed ID: 16899113
[TBL] [Abstract][Full Text] [Related]
15. The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis.
Aprelikova O; Chen K; El Touny LH; Brignatz-Guittard C; Han J; Qiu T; Yang HH; Lee MP; Zhu M; Green JE
Clin Epigenetics; 2016; 8():38. PubMed ID: 27081402
[TBL] [Abstract][Full Text] [Related]
16. Identification of novel Myc target genes with a potential role in lymphomagenesis.
Marinkovic D; Marinkovic T; Kokai E; Barth T; Möller P; Wirth T
Nucleic Acids Res; 2004; 32(18):5368-78. PubMed ID: 15477387
[TBL] [Abstract][Full Text] [Related]
17. IBTK contributes to B-cell lymphomagenesis in Eμ-myc transgenic mice conferring resistance to apoptosis.
Vecchio E; Golino G; Pisano A; Albano F; Falcone C; Ceglia S; Iaccino E; Mimmi S; Fiume G; Giurato G; Britti D; Scala G; Quinto I
Cell Death Dis; 2019 Apr; 10(4):320. PubMed ID: 30975981
[TBL] [Abstract][Full Text] [Related]
18. Combined serum and tissue proteomic study applied to a c-Myc transgenic mouse model of hepatocellular carcinoma identified novel disease regulated proteins suitable for diagnosis and therapeutic intervention strategies.
Ritorto MS; Borlak J
J Proteome Res; 2011 Jul; 10(7):3012-30. PubMed ID: 21644509
[TBL] [Abstract][Full Text] [Related]
19. MINCR is a MYC-induced lncRNA able to modulate MYC's transcriptional network in Burkitt lymphoma cells.
Doose G; Haake A; Bernhart SH; López C; Duggimpudi S; Wojciech F; Bergmann AK; Borkhardt A; Burkhardt B; Claviez A; Dimitrova L; Haas S; Hoell JI; Hummel M; Karsch D; Klapper W; Kleo K; Kretzmer H; Kreuz M; Küppers R; Lawerenz C; Lenze D; Loeffler M; Mantovani-Löffler L; Möller P; Ott G; Richter J; Rohde M; Rosenstiel P; Rosenwald A; Schilhabel M; Schneider M; Scholz I; Stilgenbauer S; Stunnenberg HG; Szczepanowski M; Trümper L; Weniger MA; ; Hoffmann S; Siebert R; Iaccarino I
Proc Natl Acad Sci U S A; 2015 Sep; 112(38):E5261-70. PubMed ID: 26351698
[TBL] [Abstract][Full Text] [Related]
20. Identification of synthetic lethality of PRKDC in MYC-dependent human cancers by pooled shRNA screening.
Zhou Z; Patel M; Ng N; Hsieh MH; Orth AP; Walker JR; Batalov S; Harris JL; Liu J
BMC Cancer; 2014 Dec; 14():944. PubMed ID: 25495526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
